Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 7/20 | 1.00 |
| ▸ | PYGM | P11217 | 3/20 | 0.67 |
| ▸ | TK1 | P04183 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorivudine SCHEMBL4658822 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 | |
| Sorivudine SCHEMBL16555082 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 | |
| Sorivudine SCHEMBL1981707 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 | |
| Sorivudine SCHEMBL3503357 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 | |
| Sorivudine SCHEMBL16555084 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 | |
| Sorivudine SCHEMBL13413053 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 | |
| Sorivudine SCHEMBL13447883 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 | |
| Sorivudine SCHEMBL4292930 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 | |
| Sorivudine SCHEMBL3503360 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 | |
| Sorivudine SCHEMBL5511785 | 1.00 | TK2 (1.00) | TK2PYGMTK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3801 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| US-20250213469-A1 | DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES | PULMOCURES ILAC EGITIM DANISMANLIK A.S. | 2025-07-03 | — | — | US | claimed |
| US-12337065-B2 | Compositions for treating viral infections and methods for same | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2025-06-24 | — | — | US | claimed |
| US-20250136682-A1 | ANTI-SIGLEC-3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | ACADEMIA SINICA (TW) | 2025-05-01 | — | — | US | claimed |
| EP-4504263-A1 | ANTI-SIGLEC-3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | Academia Sinica (TW) | 2025-02-12 | — | — | EP | claimed |
| EP-4493276-A1 | DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES | PULMOCURES ILAC EGITIM DANISMANLIK A.S. (TR) | 2025-01-22 | — | — | EP | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| US-5380727-A | Antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative | BIO-MEGA, INC. (CA) | 1995-01-10 | — | — | US | claimed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0618226-A1 | Inhibitors of herpes viral ribonculeotide reductase | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-10-05 | — | — | EP | claimed |
| WO-1994020528-A1 | INHIBITORS OF HERPES VIRAL RIBONUCLEOTIDE REDUCTASE | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-09-15 | — | — | WO | claimed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | claimed |
| EP-0560274-A1 | Antiherpes peptide derivatives having a ureido N-terminus | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-0493770-A2 | Antiherpes compositions | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1992-07-08 | — | — | EP | claimed |
| EP-0493767-A2 | Synergistic combination for treating herpes infections | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1992-07-08 | — | — | EP | claimed |
| WO-1991000867-A1 | 5'-DIPHOSPHOHEXOSE NUCLEOSIDE PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-01-24 | — | — | WO | claimed |